Alex Luke

Neurohospitalist | Former KUMC Vascular Neurology Fellow | Former Academic Initiatives Specialist | @UMKCmedschool Grad | @MissouriWestern Biochemistry Grad

[Alex Luke @DrAlexLuke]

This image may help elucidate hyperlipidemia management for secondary stroke prevention in your stroke/TIA patients (generated using Gemini). Please read more below and stay tuned for next week!

https://t.co/3YrncWsMG3
https://t.co/H8dRS4pbLo
https://t.co/FTaGeT4yWB

[Alex Luke @DrAlexLuke]

On this week's edition of #tweetorial Tuesday:

Statins, they're just for the heart, right? 🫀
Wrong. Hyperlipidemia management is one of the biggest levers we have to prevent a second stroke—but many survivors never reach guideline-directed LDL targets
#MedEd #NeuroTwitter

[Alex Luke @DrAlexLuke]

Questions remain about optimal LDL thresholds in different stroke subtypes, long‑term safety of ultra‑low LDL levels, and how best to personalize therapy in complex patients

Ongoing and future trials will likely refine targets and broaden the evidence base for non‑statin agents

[Alex Luke @DrAlexLuke]

14/ For now, the LAA is both crucial and controversial in stroke prevention. The data from CLOSURE-AF and CHAMPION-AF should push us away from “closure vs anticoagulation” as a binary decision and toward individualized, risk-based strategies in stroke prevention

[Alex Luke @DrAlexLuke]

1/ This week on Tweetorial Tuesday (on a Friday 🤫)!

Is the left atrial appendage the most important—and most overlooked—target in stroke prevention? Two recent NEJM trials just added fuel to that debate ❤️🧠

[Alex Luke @DrAlexLuke]

13/ As for the takeaway? It seems some of the push for devices may be driven by patient preference to have one procedure and never look back, compared to a lifelong prescription. Based on these trials:
- For most AF patients who can tolerate DOACs, they remain first-line